首页> 美国政府科技报告 >Modulation of Paclitaxel Antitumor Effects by Calcitriol: Preclinical Studies of Mechanism, Toxicity and Efficacy in Prostate Cancer
【24h】

Modulation of Paclitaxel Antitumor Effects by Calcitriol: Preclinical Studies of Mechanism, Toxicity and Efficacy in Prostate Cancer

机译:骨化三醇对紫杉醇抗肿瘤作用的调节:前列腺癌机制,毒性和疗效的临床前研究

获取原文

摘要

Vitamin D or 1,25-dihydroxycholecalciferol (calcitriol)inhibits proliferation, induces differentiation and modulates cell cycle progression in a variety of normal and malignant cells. We demonstrated in the Dunning rate prostate cancer(Mat-Ly-Lu) and a human xenograft model (PC-3) that calcitriol has significant anti-proliferative activity, arrests cells in GO/G1, modulates expression of p27 and p21, induces PARP cleavage and significantly enhances the anti-tumor activity of conventional chemotherapeutic agents, especially paclitaxel. In addition, we have completed a phase I trial of high dose calcitriol in which we determined the MTD of subcutaneous calcitriol and calcitriol pharmacokinetics. Since paclitaxel has considerable potential as an agent for the therapy of prostate cancer and calcitriol potentiates paclitaxel and is active as a single agent, we propose to examine further the therapeutic potential of calcitriol by: (1) determining the schedule and time-dependent parameters of calcitriol and paclitaxel for optimum potentiating activity in MLL and PC-3 prostate cancer models; (2) determining the role of calcitriol in the induction of apoptosis and the role of changes in intracellular Ca + 2 in these activities; and (3) evaluating the toxicities, MTD, pharmacokinetics and pharmacodynamics and activity of paclitaxel and calcitriol when administered to patients with prostate cancer.

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号